Jeffrey Huang

Dr. Jeffrey Huang

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Christopher Lawrence RennieChristopher Lawrence Rennie
Christopher Lawrence Rennie
DIDylan Irvine
Dylan Irvine
EHEvan Huang
Evan Huang
Jeffrey HuangJeffrey Huang
Jeffrey Huang
Aims and Objectives: To consolidate and summarize the current literature surrounding the use of music therapy as an effective noninvasive adjunct to conventional cancer therapy, especially as a low-risk alternative for pain management and anesthetic use in cancer patients. Background: Current studies have proposed that music therapy may be effective as a noninvasive adjunct to conventional cancer therapy in managing numerous outcomes in cancer patients. However, the findings of these investigations have not been consolidated and analyzed on a large scale. Therefore, focusing a systematic review on the effects of music therapy as an adjunct to conventional cancer therapy would give a better understanding of which intervention approaches are associated with better clinical outcomes for cancer patients. Design: A systematic review. Methods: A review of randomized controlled trials to evaluate the effectiveness of music therapy in physical, cognitive, and psychosocial outcomes for cancer patients alone or in conjunction with standard therapy was implemented. We conducted searches using the PubMed/MEDLINE, CINAHL, and Cochrane Library databases for all articles meeting the search criteria up until the time of article extraction in May, 2022. Only studies published in English were included. Two reviewers independently extracted data on participant and intervention characteristics. The main outcome variables included pain, anxiety, quality of life, mood, sleep disorders, fatigue, heart rate, blood pressure, respiratory rate, and oxygen saturation. Results: Of the 202 initially identified articles, 25 randomized controlled trials met the inclusion criteria for evaluation. Of the 25 studies, 23 (92.0%) reported statistically and clinically significant improvements across the outcome variables. Two of the studies (8.00%) found no significant positive effect from music therapy in any of the aforementioned outcomes variables. Conclusion: Music therapy, both as a standalone treatment and when used in conjunction with other pharmacologic and nonpharmacologic modalities, has a generally beneficial effect across several physiologic and psychosocial aspects of cancer.

1 March 2023 in Medicina
Verified
Journal Article
Open access
PDF file
EHEvan Huang
Evan Huang
Jeffrey HuangJeffrey Huang
Jeffrey Huang
Background and Objectives: Music interventions have been used for patients with cancer to meet their psychological, physical, social, and spiritual needs. This review identified the efficacy of music therapy among adult patients with colorectal cancer (CRC). Materials and Methods: We searched the PubMed/MEDLINE, CINAHL, and Cochrane Library databases. Only randomized controlled studies reported in English of patients with CRC were included. Two reviewers independently extracted data on patients and intervention measurements. The main outcomes included pain, anxiety, quality of life, mood, nausea, vomiting, vital signs. Results: A total of 147 articles were identified from the search. A total of 10 studies were included in the review. Nine out of the ten studies (90%) showed statistically and clinically significant improvements across the outcome variables. Only one study (10%) found no significant positive effect from music therapy in any of the measured outcomes. Among the seven studies measuring pain as an outcome, four studies (57%) demonstrated that music therapy reduced pain. Three studies (75%) showed that MT reduced anxiety. Conclusions: This systemic review indicates that music therapy might help reduce pain and anxiety for cancer patients, including those with colorectal cancer, who are receiving treatment in palliative care, inpatient care and outpatient care settings.

1 September 2010 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
Jeffrey HuangJeffrey Huang
Jeffrey Huang

3 May 2016 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
PDF file
Jeffrey HuangJeffrey Huang
Jeffrey Huang
HGHuan Gao
Huan Gao

15 December 2023 in International Journal of Clinical and Health Psychology
Verified
Journal Article
Open access
LALeila Azari
Leila Azari
HHHoma Hemati
Homa Hemati
RTRonia Tavasolian
Ronia Tavasolian
SSSareh Shahdab
Sareh Shahdab
STStephanie Tomlinson
Stephanie Tomlinson
ATAmir Alishahi Tabriz
Amir Alishahi Tabriz
Management of depression in the oncology population includes supportive psychotherapeutic interventions with or without psychotropic medication, which take time to demonstrate effectiveness. Fast-acting interventions, like ketamine, can provide a rapid antidepressant effect; however, there has been limited research on effects of ketamine among cancer patients. The objective of this review is to provide an overview of research on the efficacy and safety of ketamine on depression in patients with cancer. We reviewed the published literature in MEDLINE® (via PubMed®), EMBASE, and Scopus from 1 January 1982 to 20 October 2022. We screened the retrieved abstracts against inclusion criteria and conducted a full‐text review of eligible studies. Following extraction of data from included studies, we used a framework analysis approach to summarize the evidence on using ketamine in patients with cancer. All 5 included studies were randomized clinical trials conducted in inpatient settings in China. In all included studies ketamine was administered intravenously. Three studies used only racemic ketamine, and two studies used both S-ketamine and racemic ketamine. All included studies reported ketamine a tolerable and effective drug to control depression symptoms. Included studies showed administration of sub-anesthesia ketamine significantly improves postoperative depression among patients with cancer.

6 August 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
LALeila Azari
Leila Azari
HHHoma Hemati
Homa Hemati
RTRonia Tavasolian
Ronia Tavasolian
SSSareh Shahdab
Sareh Shahdab
STStephanie Tomlinson
Stephanie Tomlinson
ATAmir Alishahi Tabriz
Amir Alishahi Tabriz
Managing cancer-related pain poses significant challenges, prompting research into alternative approaches such as ketamine. This systematic review aims to analyze and summarize the impact of ketamine as an adjuvant to opioid therapy for cancer-related pain. We conducted a literature review in MEDLINE, EMBASE, and Scopus from 1 January 1982 to 20 October 2023. Abstracts were screened against inclusion criteria, and eligible studies underwent a full-text review. Data was extracted from the included studies, and a framework analysis approach summarized the evidence regarding ketamine’s use in patients with cancer. A total of 21 randomized clinical trials were included, and the quality of all the included studies was good or fair. Significant improvements in pain scores and reduced morphine consumption were consistently observed with intravenous ketamine administration for postoperative pain control, particularly when combined with other analgesics such as morphine. Ketamine was less effective when used as an analgesic for chronic pain management, with several studies on neuropathic pain or chemotherapy-induced neuropathy finding minimal significant effect on reduction of pain scores or morphine requirements. The efficacy of ketamine in pain management appears to depend on factors such as dosage, route of administration, and patient population.